The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck also lowered revenue guidance for 2025. 10 stocks we like better than Merck › The stock for pharmaceutical giant Merck ...

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Merck (MRK) stock is in focus as the company secures $700M from Blackstone to advance cancer therapy sacituzumab tirumotecan ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc.

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...